Ami Bhatt and Jagat Narula discuss the global impact of rheumatic heart disease, its challenges, and ongoing efforts for ...
Three countries with different systems achieved similar levels of control, indicating that efforts to lessen CV risk should ...
The Centers for Medicare & Medicaid Services is weighing whether to cover TAVI in asymptomatic severe aortic stenosis, as ...
Twenty years of data from New England highlight geographical challenges, which some say may merit a rethink of STEMI care.
The 2026 dyslipidemia guidelines offer “a chance to save lives at scale.” But statins alone can’t solve the problem.
Strait Access Technologies e-mail: info@sat.za.com, a medical technology company developing next-generation cardiovascular ...
Absent contraindications, optimal medical therapy for heart failure with preserved ejection fraction (HFpEF) should include a ...
Experts hope the FAI score can become the next big tool in personalized risk assessment, though costs remain unknown.
With expectations to work after hours and a growing administrative burden, some say “radical” action is needed.
The US Food and Drug Administration has approved enlicitide (Lipfendra) as the first oral PCSK9 inhibitor for reducing LDL ...
The study serves as a reminder of what can happen when disease progresses in asymptomatic patients, David Cohen says.
This month: online GLP-1 concerns, psychological impact of wearables, sexual and gender minority health insights, and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results